NCT01811472View on ClinicalTrials.gov

Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
DRUG

LCQ908

LCQ908 5 mg, 10 mg, 20 mg tablets

DRUG

placebo

Matching placebo of LCQ908 5 mg, 10 mg, 20 mg tablets.

Trial Locations (11)

23298

Novartis Investigative Site, Richmond

33126

Novartis Investigative Site, Miami

33319

Novartis Investigative Site, Tamarac

36608

Novartis Investigative Site, Mobile

38801

Novartis Investigative Site, Tupelo

40213

Novartis Investigative Site, Louisville

75093

Novartis Investigative Site, Plano

77030

Novartis Investigative Site, Houston

92114

Novartis Investigative Site, San Diego

96814

Novartis Investigative Site, Honolulu

32610-0277

Novartis Investigative Site, Gainesville

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY